Cargando…

Von Hippel-Lindau Disease and the Eye

Retinal hemangioblastoma (also referred to as retinal capillary hemangioma) is a benign lesion originating from the endothelial and glial components of the neurosensory retina and optic nerve head. Historically known as a manifestation of the von Hippel-Lindau (VHL) disease, it can be seen as an iso...

Descripción completa

Detalles Bibliográficos
Autores principales: Karimi, Saeed, Arabi, Amir, Shahraki, Toktam, Safi, Sare
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PUBLISHED BY KNOWLEDGE E 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001024/
https://www.ncbi.nlm.nih.gov/pubmed/32095212
http://dx.doi.org/10.18502/jovr.v15i1.5950
_version_ 1783494156790792192
author Karimi, Saeed
Arabi, Amir
Shahraki, Toktam
Safi, Sare
author_facet Karimi, Saeed
Arabi, Amir
Shahraki, Toktam
Safi, Sare
author_sort Karimi, Saeed
collection PubMed
description Retinal hemangioblastoma (also referred to as retinal capillary hemangioma) is a benign lesion originating from the endothelial and glial components of the neurosensory retina and optic nerve head. Historically known as a manifestation of the von Hippel-Lindau (VHL) disease, it can be seen as an isolated finding or in association with some rare ocular conditions. In addition to characteristic ophthalmoscopic features, results of numerous ancillary tests including angiography, ultrasound, optical coherence tomography, and genetic tests may support the diagnosis and differentiate it from similar conditions. Because of serious life-threatening complications of VHL disease, every ocular approach to retinal hemangioblastomas should be in relationship with additional multidisciplinary diagnostic and therapeutic efforts. In addition, any patient with actual or probable diagnosis of VHL disease should be screened for ocular involvement. Unfavorable visual loss can occur early, and ocular complications of VHL range from exudative retinopathy to tractional retinal detachment, neovascular glaucoma, and phthisis bulbi. Accordingly, various treatment methods have been tested with overall acceptable responses, including photocoagulation, cryotherapy, photodynamic therapy, plaque radiotherapy, vitrectomy, and more novel intravitreal injections of anti-vascular endothelial growth factors and propranolol.
format Online
Article
Text
id pubmed-7001024
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher PUBLISHED BY KNOWLEDGE E
record_format MEDLINE/PubMed
spelling pubmed-70010242020-02-24 Von Hippel-Lindau Disease and the Eye Karimi, Saeed Arabi, Amir Shahraki, Toktam Safi, Sare J Ophthalmic Vis Res Review Article Retinal hemangioblastoma (also referred to as retinal capillary hemangioma) is a benign lesion originating from the endothelial and glial components of the neurosensory retina and optic nerve head. Historically known as a manifestation of the von Hippel-Lindau (VHL) disease, it can be seen as an isolated finding or in association with some rare ocular conditions. In addition to characteristic ophthalmoscopic features, results of numerous ancillary tests including angiography, ultrasound, optical coherence tomography, and genetic tests may support the diagnosis and differentiate it from similar conditions. Because of serious life-threatening complications of VHL disease, every ocular approach to retinal hemangioblastomas should be in relationship with additional multidisciplinary diagnostic and therapeutic efforts. In addition, any patient with actual or probable diagnosis of VHL disease should be screened for ocular involvement. Unfavorable visual loss can occur early, and ocular complications of VHL range from exudative retinopathy to tractional retinal detachment, neovascular glaucoma, and phthisis bulbi. Accordingly, various treatment methods have been tested with overall acceptable responses, including photocoagulation, cryotherapy, photodynamic therapy, plaque radiotherapy, vitrectomy, and more novel intravitreal injections of anti-vascular endothelial growth factors and propranolol. PUBLISHED BY KNOWLEDGE E 2020-02-02 /pmc/articles/PMC7001024/ /pubmed/32095212 http://dx.doi.org/10.18502/jovr.v15i1.5950 Text en Copyright © 2020 Karimi et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Review Article
Karimi, Saeed
Arabi, Amir
Shahraki, Toktam
Safi, Sare
Von Hippel-Lindau Disease and the Eye
title Von Hippel-Lindau Disease and the Eye
title_full Von Hippel-Lindau Disease and the Eye
title_fullStr Von Hippel-Lindau Disease and the Eye
title_full_unstemmed Von Hippel-Lindau Disease and the Eye
title_short Von Hippel-Lindau Disease and the Eye
title_sort von hippel-lindau disease and the eye
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001024/
https://www.ncbi.nlm.nih.gov/pubmed/32095212
http://dx.doi.org/10.18502/jovr.v15i1.5950
work_keys_str_mv AT karimisaeed vonhippellindaudiseaseandtheeye
AT arabiamir vonhippellindaudiseaseandtheeye
AT shahrakitoktam vonhippellindaudiseaseandtheeye
AT safisare vonhippellindaudiseaseandtheeye